BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 26331440)

  • 1. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
    Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L
    Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
    Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Thase ME; Pritchett YL; Ossanna MJ; Swindle RW; Xu J; Detke MJ
    J Clin Psychopharmacol; 2007 Dec; 27(6):672-6. PubMed ID: 18004135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
    Mallinckrodt CH; Prakash A; Houston JP; Swindle R; Detke MJ; Fava M
    Neuropsychobiology; 2007; 56(2-3):73-85. PubMed ID: 18037817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline patient characteristics associated with placebo remission and their impact on remission with duloxetine and selected SSRI antidepressants.
    Nelson JC; Zhang Q; Kelin K; Eriksson E; Deberdt W; Berk M
    Curr Med Res Opin; 2013 Jul; 29(7):827-33. PubMed ID: 23581532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
    Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
    J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP; Loft H; Olsen CK
    Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM; Myers AL; Marangell LB; Ahl J; Prakash A; Thase ME; Kornstein SG
    Hum Psychopharmacol; 2012 Jan; 27(1):47-56. PubMed ID: 22241678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duloxetine in the treatment of major depressive disorder: an open-label study.
    Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
    BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early symptom change prediction of remission in depression treatment.
    Katz MM; Meyers AL; Prakash A; Gaynor PJ; Houston JP
    Psychopharmacol Bull; 2009; 42(1):94-107. PubMed ID: 19204654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial.
    Alaka KJ; Noble W; Montejo A; Dueñas H; Munshi A; Strawn JR; Lenox-Smith A; Ahl J; Bidzan L; Dorn B; Ball S
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):978-86. PubMed ID: 24644106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
    Blier P; Gommoll C; Chen C; Kramer K
    J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
    Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
    J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.